The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    The next big issue facing dietary supplements — You be the CEO

    Dr. Mark Moyad (photo) is Director of Preventive and Alternative Medicine at the University of Michigan Medical Center in Ann Arbor. His thoughts about the FDA’s plan to establish good manufacturing regulations for dietary supplements are published in Urology Times.

    He also looks to the next big issue that will confront the supplement industry.

    Once you know the issues, you can play the role of the pharmaceutical executive and decide if your product “Best Prostate Health” should be withdrawn from the market.

    The real dilemma with supplements, according to Dr. Moyad, is shifting to “how companies decide what ingredients they put into their products.” Formulas are protected under patent laws, which means manufacturers can’t use exactly what was successful in a specific clinical trial.

    Furthermore, companies must be willing to make a medical/business decision when to keep or remove ingredients shown to be ineffective in clinical trials. “Why,” asks Dr. Moyad, “should a manufacturer charge a fortune for a pill containing a high dose of saw palmetto [for example] when the latest study of this supplement shows that it doesn’t work?”

    He says that reputable manufacturers should acknowledge the failure of a supplement to impact disease in a definitive trial rather than invent excuses as to why the study was flawed. The bottom line is “they would simply remove the product, admit the failure, and move on.”

    That sounds like good advice, and applicable to big as well as little pharma.

    You be the pharmaceutical executive.
    After years of data supporting the role of lycopene and saw palmetto for prostate health, contrary views are emerging. Your fictional product, “Best Prostate Health,” contains lycopene, saw palmetto, selenium, beta sitosterol, zinc, amino acids, stinging nettles, and vitamin B6. Based on a negative study of saw palmetto and these negative reports on lycopene here and here, what do you do?

    • Withdraw the product from the market.
    • Remove just the saw palmetto.
    • Remove just the lycopene.
    • Make no change until the FDA requires it.

    One more factor to consider. The net profit from sales of Best Prostate Health is $60 million annually.

    8/9/07 13:39 JR

    Leave a Comment

    You must be logged in to post a comment.